| Catalog Code: | NB200-191 |
| Product Type: | Primary Antibody |
| Product Name: | DDX-6 Antibody |
| List Price: | 300 |
| Clonality: | Polyclonal |
| Gene ID: | 1656 |
| Host: | Rabbit |
| Product Description: | Rabbit Polyclonal anti-DDX-6 |
| Cross Reactivity: | Human. Other species have not been tested. |
| Species Summary: | Hu |
| Background: | DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and m |
| Alternate Names: | anti-DDX6 antibody, anti-DDX-6 antibody, anti-DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 antibody, anti-HLR2 antibody, anti-HLR-2 Helicase- RNA-Nuclear 2 antibody, anti-P54 RNA Helicase antibody, anti-RCK antibody, anti-Breakpoint in RC-K8 B-cell lymphoma c |
| Immunogen: | The epitope maps to a region between residues 1 and 50 of human DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 using the numbering given Swiss-Prot entry P26196 (GeneID 1656). |
| Specificity: | NB 200-191 is specific for human DDX6 protein. |
| Buffer: | TBS with 0.1% BSA containing 0.09% sodium azide |
| Packaging: | 0.1 ml of affinity purified rabbit sera |
| Package Size: | 0.1 ml |
| Concentration: | 1 mg/ml |
| Uses: | Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use. Suggested starting dilutions are as follows. Western Blot: 1:5,000-1:15,000 Immunoprecipitation: 2-5 ug/ml Histo/Cytochem |
| Application Summary: | WB, IP |
| Product References: | 1. Nonhoff, U., Ralser, M., Welzel, F., Piccini, I., Balzereit, D., Yaspo, M.-L., Lehrach, H., and Krobitsch, S. (2007) Ataxin-2 Interacts with the DEAD/H-Box RNA Helicase DDX6 and Interferes with P-Bodies and Stress Granules, E06-12-1120. |
| Notes Main: | Blocking peptide is available or can be made for this item. Lead time is 3 days to 4 weeks. Price is $ 150/0.25 ml (or 50 ug). Please enquire availability. |
|